When we attend a court of justice, or are presented with government policy, or have a limited data set on which to recommend consensus clinical guidelines ... it is based upon expert opinion.
MOIS actually prescribes these cytotoxic drugs. In fact, it is likely the only opportunity any of us will ever have to hear the opinion of an oncologist.
Furthermore, the accessibility and use of SRX is determined by these select few specialists in developed economies (oncologists).
I hope this helps you interpret his/her plain English statement.
Roger Montgomery on Sirtex, page-90
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.3¢ |
Change
-0.003(1.61%) |
Mkt cap ! $63.66M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.5¢ | 15.0¢ | $55.61K | 358.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2727800 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 96753 | 3 |
View Market Depth
| Last trade - 11.16am 10/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |